X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

IP protections found to be critical to life-science innovation and investment

By Jay Taylor  |    April 7, 2016
A new report by the Information Technology and Innovation Foundation (ITIF) has found intellectual property (IP) protections to be crucial to stimulating risk-taking and innovation. The study, How...   Read More

Time to enforce the rules that protect American ideas, brands and inventions

By Chris Moore  |    March 1, 2016
Earlier today, PhRMA joined organizations representing every sector of America’s knowledge economy at a public hearing in Washington that will inform the federal government’s annual “Special 301”...   Read More

Time for Canada to catch up on intellectual property

By Mark Grayson  |    February 18, 2016
Last week, the U.S. Chamber of Commerce’s Global Intellectual Property Center (GIPC) released its fourth annual International IP Index. The Index, which measures the intellectual property (IP)...   Read More

Canada’s innovation opportunity

By Jay Taylor  |    February 11, 2016
Next month’s visit of Prime Minister Justin Trudeau to Washington is a chance to strengthen a vital trade and investment partnership and to resolve problems left over by Canada’s previous...   Read More

Canada’s chance to reform its approach to innovation

By Jay Taylor  |    February 5, 2016
Intellectual property drives and sustains research, development and delivery of valuable new treatments and cures for patients who need them around the world. America’s world-leading...   Read More

5 Reasons why biopharmaceutical patents are different

By Mark Grayson  |    September 10, 2015
Intellectual property protection has deep, historical roots in the United States.  Article I, Section 8 of the U.S. Constitution expressly recognizes the role of patents to “promote the Progress...   Read More

Fact Check Friday: The Truth about IPR and Biopharmaceutical Patents

By Tina Stow  |    July 31, 2015
Today, we’re pleased to be kicking off our newest Catalyst blog series: Fact Check Friday. We’ll be using this space to separate truth from fiction and set the record straight when the rhetoric...   Read More

Patient Groups, Members of Congress and Other State-Based Stakeholders Agree: Stop the Abuse of Biopharmaceutical Patents

By Tina Stow  |    July 28, 2015
As Congress considers patent legislation known as H.R. 9, the Innovation Act, and S. 1137, the PATENT Act, health care leaders – from patient groups to Members of Congress to trade associations –...   Read More

Week in Review: The Latest from PhRMA

By Priscilla VanderVeer  |    May 22, 2015
High Out-of-Pocket Costs Hurt Patients: Even with health coverage, approximately 31 million Americans were considered “underinsured” last year due to high deductibles and increasing out-of-pocket...   Read More

Patents: More Important to Biopharmaceutical Sector than Other Industries

By Setareh Samii  |    May 18, 2015
According to Abraham Lincoln, the patent system “secured to the inventor for a limited time exclusive use of his inventions, and thereby added the fuel of interest to the fire of genius in the...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates